Genelux Investor Presentation Deck

Highlights 24600 GENELUX Olvi-Vec: De-risked late-stage Clinical Program Ongoing pivotal trial in late-stage Ovarian Cancer, SCLC and planned Phase 2 trial Adjuvant Maintenance NSCLC CHOICETM Platform; Broad and Diverse Discovery Engine Library with over 500 novel vaccinia strains and 110+ transgenes Validating Strategic Partnerships Newsoara Biopharma (Greater China rights) initiated a Phase 1b/2 clinical trial with Olvi-Vec in small-cell lung cancer and ELIAS Animal Health (global rights) is preparing a canine efficacy study with V-VET1 Focused Commercial Strategy US launch in Ovarian Cancer initially; strategic partnerships for ex-US rights Estimated Billion Dollar Plus Annual Market Opportunity in the U.S. Potential beyond this in numerous clinical settings 32

View entire presentation